Please assess the completion status of the following clinical trial:

Trial Title: Dimethyl Fumarate for Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 18-65 years at screening;~2. Diagnosis of OSA as confirmed by previous clinical sleep study (polysomnography, PSG);~3. Refusal, inability, or high reluctance to use CPAP regularly for treatment of OSA, despite medical advice;~4. Willingness to undergo repeat sleep study (PSG) and blood studies;~5. Normal immune cell counts, as evidenced by complete blood count (CBC) done at screening~Exclusion Criteria:~1. Regular use of CPAP within the last 2 months~2. Physical, psychiatric or cognitive impairment that prevents informed consent, PSG, or reliable follow-up;~3. Cardiac conditions that may increase sleep apnea severity (e.g., congestive heart failure or recent heart attack);~4. Current successful treatment for obstructive or central sleep apnea, for example by CPAP, and patient agreement to continue with that treatment;~5. History of surgical treatment for OSA within past 6 months, or subsequent to last PSG confirmation that OSA is present;~6. Active nervous system diseases that may predispose subjects to OSA;~7. Systemic autoimmune disease that could increase inflammation and influence apnea severity (such as rheumatoid arthritis or lupus);~8. Pregnancy or breastfeeding;~9. Use of immunotherapies or immunosuppressants, currently or within past 6 months;~10. Anticipated initiation or dose change in tricyclic antidepressants, selective serotonin uptake inhibitors, or related compounds;~11. Participants with a history of active, serious or persistent infections.~12. Participants with recent surgery (within 3 months prior to screening), or anticipated surgery during the length of the study.~13. Systemic steroid use within the last 2 months (does not include local steroid injections or intranasal steroid spray);~14. Current diagnosis of cancer that is not considered to be cured or in remission by the treating physician, cancer treatment of any kind within the last 6 months prior to screening (chemo, radiation, surgery), or anticipated cancer treatment during the length of the study;~15. History of a lymphoproliferative disorder (such as leukemia);~16. History of Multiple Myeloma~17. History of decreased immune cell counts per a blood test known as a CBC, specifically lymphocyte counts less than 1.2 K/μL at screening.~18. Refusal to use at least one reliable method of birth control (for women of childbearing age)~19. Newly diagnosed (within 2 months) OSA subjects who have an AHI \> 30 and history of serious, recent, or unstable cardiovascular disease (including but not limited to recent MI, recent stroke/TIA, or unstable angina)~20. Participants who report previous motor vehicle accidents or near-misses presumed to be due to excessive sleepiness while driving.~21. Any other condition or treatment that in the opinion of the investigator could affect subject safety or study eligibility.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dimethyl Fumarate (Tecfidera®) capsules (Type: ACTIVE_COMPARATOR): The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).